The Review Platform For Content That Has To Be Right.

No more bottlenecked MLR reviews, buried evidence, or last-minute compliance scrambles.

12
Claims identified
6
Fully Supported
2
Supported
2
Unsupported
Collateral PDF Content
1
Claim 01Link Selected

Catheter-associated urinary tract infections account for approximately 40% of all healthcare-associated

Matched with Items in Claims Library
CLM-284795% MatchRecommended

"Catheter-associated urinary tract infections account for approximately 40% of all healthcare-associated infections, with biofilms forming on catheter surfaces within 24–48 hours and reducing antibiotic susceptibility by up to 1,000-fold."

ViewLinked
CLM-284765% Match

"Diagnostic tools can closely match infection patterns to spatial health data models, enabling clinical claims to be validated with higher confidence across diverse patient populations."

ViewLink Claim ☐
Hero Mockup

Trusted By

MarFlow Switzerland
biorad medisys
Medtimo

Antimicrobial Catheter Surface Modifications: A Review

Catheter-associated urinary tract infections remain a major complication of urinary catheterization. This review examines antimicrobial surface modifications designed to reduce biofilm formation, bacterial colonization, and device-related infection risk in clinical settings.

Introduction

Catheter-associated urinary tract infections account for approximately 40% of all healthcare-associated infections...

Materials & Methods
Recent studies have explored a range of antimicrobial surface modifications, including silver-based coatings, nitric oxide-releasing polymers, and hydrophilic surfaces functionalized with antimicrobial peptides. In vitro and in vivo models have been used to evaluate coating durability, antimicrobial efficacy, and biocompatibility.
Results
Clinical trials demonstrate that silver-alloy coated catheters reduced the rate of catheter-associated bacteriuria by 32% compared to standard uncoated catheters.
Claim 1
Catheter-associated urinary tract infections account for approximately 40% of all healthcare-associated infections
view details
Claim 2
An estimated 150,000–450,000 catheter-associated urinary tract infection cases are reported annually in the United States.
view details
Claim 3
Biofilms can form on catheter surfaces within 24–48 hours of insertion.

Scientific content creation is moving at 2026 speed. Validation is still stuck in the 90's

Animated illustration
Vero V

Vero is a content compliance and lifecycle platform built for Pharma, Medtech, and Labtech teams. Vero connects claim validation, approved content, and compliant content creation in one workflow. Validate what you say, reuse what’s approved, and create what comes next.

Made For Cross-Functional Teams
Marketing | Regulatory | Medical
VeroClaim

Validate Claims Against Trusted Evidence.

Vero identifies claims, finds relevant evidence, and shows reviewers what supports each one.

Claim 01

Our catheters reduce infection rates by 40% compared to traditional devices

3 Evidence Matches
Fully supported
Claims Library EvidenceCLM 26

Catheter-associated infections pose a significant risk to patient safety. The purpose of this integrative review was to identify recent literature on catheter care practices and prevention strategies aimed at reducing infection rates.

Reference File
PDF
ISOPP, 2022.pdfDocument · 1.2 MB
View
100%
Evidence-Backed Validation
95%
Claim Accuracy
70%
Reduction In Review Time
50%
Less Manual Effort

Everything That Makes Vero Awesome

Automated Claim Extraction

Explore VeroClaim ↗
CLM-2847
95% MatchRecommended

Catheter biofilms form within 24–48 hours, driving 40% of healthcare-associated infections and reducing antibiotic susceptibility up to 1,000-fold.

View|Link

Compliant In 40+ Countries

Explore VeroClaim ↗

Select where this applies in

Countries or regions where this material will be used

Select a country
India×
USA×

Reference-Aware Expiration

Safety_Protocol_v3.docx
May 30, 2023Active
Quality_Assurance_Guidelines_B.pdf
May 30, 2023Active
Regulatory_Compliance_Checklist.pdf
May 12, 2023Expires in 3 months
Marketing_Material_ProductB_Draft.pptx
Apr 02, 2023Inactive
Explore VeroVault ↗

Automated Claim Validation & Checking

Explore VeroClaim ↗

Claim 01

Considering antiseptic or antimicrobial-coated catheters if local CAUTI rates persist despite implementation of prevention

Fully Supported
Claims Library EvidenceCLM 26
“

Exposure to chemotherapy is an occupational hazard predisposing nurses to severe health effects. The purpose of this integrative review was to identify the

Built for teams that cannot compromise on accuracy.

Mr. Lorem Ipsum
Mr. Lorem Ipsum
Role, Company

“Vero has transformed how our team manages scientific content. We spend less time searching for references, validate claims faster, and create with far greater confidence.”

Mr. Lorem Ipsum
Mr. Lorem Ipsum
Role, Company

“Vero has transformed how our team manages scientific content. We spend less time searching for references, validate claims faster, and create with far greater confidence.”

Mr. Lorem Ipsum
Mr. Lorem Ipsum
Role, Company

“Vero has transformed how our team manages scientific content. We spend less time searching for references, validate claims faster, and create with far greater confidence.”

What’s The Next Big Thing At Vero? 👀

Vero vs. Veeva PromoMats:How Vero Approaches MLR Differently
BLOG

A side-by-side look at claim validation, implementation time, and where each platform fits

Why Claims Review Becomes aBottleneck for Pharma Marketing Teams?
BLOG

The specific, fixable reasons MLR review slows down - and how to catch the gap earlier

Why Claims Review Becomes aBottleneck for Pharma Marketing Teams?
BLOG

The specific, fixable reasons MLR review slows down - and how to catch the gap earlier

Vero vs. Veeva PromoMats:How Vero Approaches MLR Differently
BLOG

A side-by-side look at claim validation, implementation time, and where each platform fits

Why Claims Review Becomes aBottleneck for Pharma Marketing Teams?
BLOG

The specific, fixable reasons MLR review slows down - and how to catch the gap earlier

Vero vs. Veeva PromoMats:How Vero Approaches MLR Differently
BLOG

A side-by-side look at claim validation, implementation time, and where each platform fits

Frequently
Asked Questions

What is Vero?

Vero is a content compliance and lifecycle platform for Pharma, Medtech, and Labtech teams. It helps teams validate claims, manage approved content and evidence, and create new content from trusted sources all in one workflow.

How does Vero check a claim?

Does Vero replace our medical, legal and regulatory reviewers?

Can VeroAsk make things up?

How is Vero different from a DAM or a traditional MLR platform?

Who is Vero built for?

What is MLR review, and where does Vero fit?